<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="Anti-VEGF agents in metastatic colorectal cancer Brought to you by Fellow 1 ÊûóÂçîÈúÜ Supervisor: ÈªÉÂúãÂüïÈÜ´Â∏´  What are vascular endothelial growth factors (VEGF) :::columns"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Anti-VEGF agents in metastatic colorectal cancer"><title>Anti-VEGF agents in metastatic colorectal cancer</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.84393096b3899db7fcf941e10b02fd94.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.021556b96a3c2bac2659a9f1cb00f8e2.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'‚Äô':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=ÊêúÂ∞ã placeholder="Ë´ãËº∏ÂÖ•ÂÉèÊòØÔºöhypertension ‰πãÈ°ûÁöÑ‰æÜÁúãÊ≤íÊúâÊ≤í‰ªÄÈ∫ºÊúâË∂£ÁöÑüé≥"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>Ëú•Ëú¥Ëä±Âúíü¶éüå±ü™¥üå≤</a></h1><div class=spacer></div><div id=search-icon><p>ÊêúÂ∞ã</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">ÊêúÂ∞ãÂúñÁ§∫</title><desc id="desc">ÊâìÈñãÊêúÂ∞ãÂúñÊ®ô</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Êòé‰∫ÆÊ®°Âºè</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>ÈªëÊöóÊ®°Âºè</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Anti-VEGF agents in metastatic colorectal cancer</h1><p class=meta>ÊúÄÂæåÊõ¥Êñ∞Êñº
Sep 18, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/Anti-VEGF%20agents%20in%20metastatic%20colorectal%20cancer.md rel=noopener>ü™ö Á∑®ËºØÂéüÂßãÊñá‰ª∂</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>üìíÁõÆÈåÑ</summary><nav id=TableOfContents><ol><li><ol><li></li></ol></li><li><a href=#what-are-vascular-endothelial-growth-factors-vegf>What are vascular endothelial growth factors (VEGF)</a></li><li><a href=#overview-of-angiogenesis-inhibitors>Overview of angiogenesis inhibitors</a></li></ol><ol><li><ol><li><a href=#esmo-2023-mcrc>ESMO 2023 mCRC</a></li><li><a href=#esmo-2023-mcrc-1>ESMO 2023 mCRC</a></li><li><a href=#esmo-2023-mcrc-2>ESMO 2023 mCRC</a></li><li><a href=#esmo-2023-mcrc-3>ESMO 2023 mCRC</a></li></ol></li></ol><ol><li><ol><li><a href=#pretreatment-assessment-and-screening>Pretreatment assessment and screening</a></li><li><a href=#monitoring-during-treatment>Monitoring during treatment</a></li></ol></li><li><a href=#risk-factors-for-adverse-consequences-of-high-blood-pressure-bp>Risk factors for adverse consequences of high blood pressure (BP)</a><ol><li><a href=#three-or-more-of-the-following-cv-risk-factors>Three or more of the following CV risk factors</a></li><li><a href=#established-or-subclinical-renal-disease-including>Established or subclinical renal disease including</a></li></ol></li><li><a href=#bevacizumab-avastin>Bevacizumab (Avastin)</a></li><li><a href=#warnings>Warnings</a><ol><li><a href=#gi-perforation>GI Perforation</a></li><li><a href=#surgery-and-wound-healing-complications>Surgery and Wound Healing Complications</a></li><li><a href=#hemorrhage>Hemorrhage</a></li><li><a href=#thromboembolism>Thromboembolism</a></li><li><a href=#hypertension>Hypertension</a></li><li><a href=#reversible-posterior-leukoencephalopathy-syndrome-rpls>Reversible Posterior Leukoencephalopathy Syndrome (RPLS)</a></li><li><a href=#proteinuria>Proteinuria</a></li><li><a href=#ocular-effects>Ocular Effects</a></li></ol></li><li><a href=#as-first-line-therapy-bevacizumab-may-be-given-with>As first-line therapy, bevacizumab may be given with</a></li><li><a href=#bevacizumab--irinotecan-fluorouracil-and-leucovorin-for-mcrc>Bevacizumab + irinotecan, fluorouracil, and leucovorin for mCRC</a><ol><li></li></ol></li><li><a href=#bev-in-combination-with-xelox-or-folfox-4-improves-progression-free-survival-in-first-line-treatment-of-mcrc>Bev in combination with XELOX or FOLFOX-4 Improves Progression-Free Survival in First-Line Treatment of MCRC</a></li><li><a href=#in-the-tribe-study-for-bevfolfoxiri>In the TRIBE study for Bev/FOLFOXIRI</a><ol><li></li></ol></li><li><a href=#comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-first-line-treatment-for-metastatic-colorectal-cancer>Comparison of Chemotherapy plus Bevacizumab vs Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer</a></li><li><a href=#fire-3>FIRE-3</a></li><li><a href=#summary>Summary</a></li><li><a href=#calgbswog-80405>CALGB/SWOG 80405</a><ol><li></li></ol></li><li><a href=#summary-1>Summary</a></li><li><a href=#paradigm>PARADIGM</a><ol><li></li></ol></li><li><a href=#continued-use-of-bevacizumab-in--progressing-after-standard-first-line-bevacizumab-based-treatment>Continued use of bevacizumab in progressing after standard first-line bevacizumab-based treatment</a><ol><li><a href=#result>Result</a></li></ol></li></ol><ol><li><a href=#bevacizumab-vs-cetuximab-in-second-line-treatment>Bevacizumab vs Cetuximab in Second-Line Treatment</a><ol><li><a href=#comparison-of-two-groups>Comparison of Two Groups</a></li></ol></li><li><a href=#aflibercept-in-combination-with-folfiri-for-metastatic-colorectal-cancer-a-randomized-phase-iii-trial>Aflibercept in Combination with FOLFIRI for Metastatic Colorectal Cancer: A Randomized Phase III Trial</a></li><li><a href=#summary-2>Summary</a><ol><li></li></ol></li><li><a href=#ziv-aflibercept-zaltrap>Ziv-Aflibercept (Zaltrap)</a></li><li><a href=#comparing-second-line-bevacizumab-and-aflibercept-in-patients-who-progressed-on-first-line-bevacizumab>Comparing second-line bevacizumab and aflibercept in patients who progressed on first-line bevacizumab</a></li><li><a href=#raise-trial>RAISE Trial</a></li><li><a href=#summary-3>Summary</a><ol><li></li></ol></li><li><a href=#ramucirumab-cyramza>Ramucirumab (Cyramza)</a></li><li><a href=#wrap-up>Wrap up</a></li></ol><ol><li><a href=#correct-regorafenib-alone>CORRECT: regorafenib alone</a><ol><li></li></ol></li><li><a href=#summary-4>Summary</a></li><li><a href=#concur-trial-with-chemo>CONCUR trial: with chemo</a></li><li><a href=#redos-trial-reduce-dose>ReDOS trial: Reduce dose</a><ol><li></li></ol></li><li><a href=#regorafenib-stivarga>Regorafenib (Stivarga)</a></li><li><a href=#regorafenib-versus-trifluridinetipiracil>Regorafenib Versus Trifluridine/Tipiracil</a></li><li><a href=#ftd-tpi-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-phase-3-trial>FTD-TPI Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Phase 3 Trial</a><ol><li></li><li><a href=#summary-5>Summary</a></li></ol></li></ol><ol><li><ol><li><a href=#and-those-with-a-poor-performance-status>and those with a poor performance status</a></li></ol></li><li><a href=#phase-ii-prodige-20>Phase II PRODIGE 20</a></li><li><a href=#bevacizumab-plus-capecitabine-in-elderly-patients-with-metastatic-colorectal-cancer-a-randomized-phase-3-trial>Bevacizumab plus Capecitabine in Elderly Patients with Metastatic Colorectal Cancer: A Randomized, Phase 3 Trial</a><ol><li><a href=#avex-trial>AVEX trial</a></li><li><a href=#summary-6>Summary</a></li><li><a href=#should-i-add-anti-vegf-in-older-adult-patients-and-those-with-a-poor-performance-status>Should I add Anti-VEGF in older adult patients and those with a poor performance status?</a></li></ol></li><li><a href=#take-home-messages>Take Home Messages</a></li></ol></nav></details></aside><a href=#anti-vegf-agents-in-metastatic-colorectal-cancer><h1 id=anti-vegf-agents-in-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Anti-VEGF agents in metastatic colorectal cancer</h1></a><a href=#brought-to-you-by-fellow-1-ÊûóÂçîÈúÜ><h4 id=brought-to-you-by-fellow-1-ÊûóÂçîÈúÜ><span class=hanchor arialabel=Anchor># </span>Brought to you by Fellow 1 ÊûóÂçîÈúÜ</h4></a><a href=#supervisor-ÈªÉÂúãÂüïÈÜ´Â∏´><h4 id=supervisor-ÈªÉÂúãÂüïÈÜ´Â∏´><span class=hanchor arialabel=Anchor># </span>Supervisor: ÈªÉÂúãÂüïÈÜ´Â∏´</h4></a><hr><a href=#what-are-vascular-endothelial-growth-factors-vegf><h2 id=what-are-vascular-endothelial-growth-factors-vegf><span class=hanchor arialabel=Anchor># </span>What are vascular endothelial growth factors (VEGF)</h2></a><p>:::columns</p><p><img src=https://i.imgur.com/b0wDlkS.png width=auto alt="Figure: height:450px"></p><p>:::split</p><ul><li>VEGFR-1,2,3</li><li>VEGF-A,B,C,D</li><li>VEGF secreted by cancer and stromal cells stimulates the proliferation and survival of endothelial cells, leading to the formation of new blood vessels</li></ul><p>:::</p><hr><a href=#overview-of-angiogenesis-inhibitors><h2 id=overview-of-angiogenesis-inhibitors><span class=hanchor arialabel=Anchor># </span>Overview of angiogenesis inhibitors</h2></a><ul><li>beva<code>ci</code>zumab (Avastin)</li><li>ziv-af<code>li</code>bercept (Zaltrap)</li><li>ramu<code>ci</code>rumab (Cyramza)</li><li>rego<code>ra</code>fenib (Stivarga)</li></ul><p>(Placental growth factorÔºåPlGF)</p><p><img src=https://i.imgur.com/kfK6uf5.png width=auto alt="bg right:50% 90%"></p><hr><a href=#quick-look-at-esmo-2023-for-mcrc><h1 id=quick-look-at-esmo-2023-for-mcrc><span class=hanchor arialabel=Anchor># </span>Quick Look at ESMO 2023 for mCRC</h1></a><img src=https://i.imgur.com/4vBx2If.png alt="Example Image" class=RLQ><hr><a href=#esmo-2023-mcrc><h3 id=esmo-2023-mcrc><span class=hanchor arialabel=Anchor># </span>ESMO 2023 mCRC</h3></a><a href=#1st-l><h4 id=1st-l><span class=hanchor arialabel=Anchor># </span>1st L</h4></a><p><img src=https://i.imgur.com/tGF8ESy.png width=auto alt="Figure: bg right:80% height:600px"></p><hr><a href=#esmo-2023-mcrc-1><h3 id=esmo-2023-mcrc-1><span class=hanchor arialabel=Anchor># </span>ESMO 2023 mCRC</h3></a><a href=#maintenance><h4 id=maintenance><span class=hanchor arialabel=Anchor># </span>maintenance</h4></a><p><img src=https://i.imgur.com/ExVIPLr.png width=auto alt="Figure: bg right:80% height:600px"></p><hr><a href=#esmo-2023-mcrc-2><h3 id=esmo-2023-mcrc-2><span class=hanchor arialabel=Anchor># </span>ESMO 2023 mCRC</h3></a><a href=#2nd-l><h4 id=2nd-l><span class=hanchor arialabel=Anchor># </span>2nd L</h4></a><p><img src=https://i.imgur.com/X3FLI9d.png width=auto alt="Figure: bg right:80% height:600px"></p><hr><a href=#esmo-2023-mcrc-3><h3 id=esmo-2023-mcrc-3><span class=hanchor arialabel=Anchor># </span>ESMO 2023 mCRC</h3></a><a href=#3rd-l><h4 id=3rd-l><span class=hanchor arialabel=Anchor># </span>3rd L</h4></a><p><img src=https://i.imgur.com/aRkoyFb.png width=auto alt="Figure: bg right:80% height:400px"></p><hr><a href=#what-should-i-consider-when-i-treat-patient-with-anti-vegfr><h5 id=what-should-i-consider-when-i-treat-patient-with-anti-vegfr><span class=hanchor arialabel=Anchor># </span>What should I consider when I treat patient with anti-VEGFR</h5></a><a href=#initial-assessment-surveillance-and-management-of-blood-pressure><h1 id=initial-assessment-surveillance-and-management-of-blood-pressure><span class=hanchor arialabel=Anchor># </span>Initial assessment, surveillance, and management of blood pressure</h1></a><img src=https://i.imgur.com/TjiMulV.png alt="Example Image" class=RLQ><hr><a href=#pretreatment-assessment-and-screening><h3 id=pretreatment-assessment-and-screening><span class=hanchor arialabel=Anchor># </span>Pretreatment assessment and screening</h3></a><ol><li>Standardized blood pressure measurements</li><li>lipid panel, electrocardiogram</li></ol><a href=#monitoring-during-treatment><h3 id=monitoring-during-treatment><span class=hanchor arialabel=Anchor># </span>Monitoring during treatment</h3></a><ol><li>Actively monitor blood pressure throughout treatment with more frequent assessments during the first cycle (when the bulk of blood pressure elevation is expected to occur)</li><li>Monitoring every two to three weeks after the first cycle</li></ol><img src=https://i.imgur.com/IPEsL8O.png alt="Example Image" class=RLQ><hr><a href=#risk-factors-for-adverse-consequences-of-high-blood-pressure-bp><h2 id=risk-factors-for-adverse-consequences-of-high-blood-pressure-bp><span class=hanchor arialabel=Anchor># </span>Risk factors for adverse consequences of high blood pressure (BP)</h2></a><ul><li>Systolic BP ‚â•160 mmHg or diastolic BP ‚â•100 mmHg</li><li>Diabetes mellitus</li><li>Established CV disease:<ul><li>Ischemic stroke, cerebral hemorrhage, or transient ischemic attack</li><li>Myocardial infarction, angina, coronary revascularization, or heart failure</li><li>Peripheral artery disease</li><li>Retinal hemorrhages or exudates and papilledema</li></ul></li></ul><hr><a href=#three-or-more-of-the-following-cv-risk-factors><h3 id=three-or-more-of-the-following-cv-risk-factors><span class=hanchor arialabel=Anchor># </span>Three or more of the following CV risk factors</h3></a><ul><li>Age (men >55 y, women >65 y)</li><li>Cigarette smoking</li><li>Dyslipidemia as measured by:<ul><li>Total cholesterol >190 mg/dL</li><li>LDL >130 mg/dL</li><li>HDL (men &lt;40 mg/dL; women &lt;46 mg/dL)</li><li>TG >150 mg/dL</li></ul></li><li>Fasting plasma glucose >100 mg/dL</li><li>Family history of premature CV disease (first-degree male relative age &lt;55 y or first-degree female relative &lt;65 y)</li></ul><hr><a href=#established-or-subclinical-renal-disease-including><h3 id=established-or-subclinical-renal-disease-including><span class=hanchor arialabel=Anchor># </span>Established or subclinical renal disease including</h3></a><ul><li>Microalbuminuria or proteinuria (>30 mg/24 h)</li><li>Cr in men >1.5 mg/dL, women >1.4 mg/dL</li><li>Calculated or eGFR &lt;60 mL/min/1.73 m2</li></ul><img src=https://i.imgur.com/VjepMkP.png alt="Example Image" class=RLQ><hr><a href=#drug-info-‚Ñπ><h4 id=drug-info-‚Ñπ><span class=hanchor arialabel=Anchor># </span>Drug Info ‚ÑπÔ∏è</h4></a><a href=#bevacizumab-avastin><h2 id=bevacizumab-avastin><span class=hanchor arialabel=Anchor># </span>Bevacizumab (Avastin)</h2></a><ul><li>Mechanism: Binds to VEGF</li><li>Dosing: <code>5‚Äì15 mg/kg</code> IV every <code>14‚Äì21 d</code><ul><li>Colorectal cancer, metastatic, in combination with fluorouracil-based chemotherapy (Avastin and bevacizumab biosimilars), first- or second-line therapy:</li><li>IV: <code>5 mg/kg every 2 weeks</code> (in combination with bolus-IFL) or <code>10 mg/kg</code> every 2 weeks (in combination with FOLFOX4).</li></ul></li><li>Mechanism: Binds to VEGF</li><li>PK/PD: T1/2 ‚àº20 d</li></ul><hr><a href=#warnings><h2 id=warnings><span class=hanchor arialabel=Anchor># </span>Warnings</h2></a><a href=#gi-perforation><h3 id=gi-perforation><span class=hanchor arialabel=Anchor># </span>GI Perforation</h3></a><ul><li>GI perforation reported;<ul><li>generally manifested as abdominal pain, nausea, vomiting, constipation, and fever.</li><li>Usually occurs within the first 50 days following initiation of bevacizumab.</li></ul></li><li>c/w fistula formation, intra-abdominal abscess.</li></ul><img src=https://i.imgur.com/cgYgVHF.png alt="Example Image" class=RLQ><hr><a href=#surgery-and-wound-healing-complications><h3 id=surgery-and-wound-healing-complications><span class=hanchor arialabel=Anchor># </span>Surgery and Wound Healing Complications</h3></a><ul><li>Wound healing and bleeding complications (including wound dehiscence)</li><li>Do not initiate bevacizumab therapy until <code>‚â•28 days</code> following major surgery and after surgical incision has fully healed.</li><li>Discontinue bevacizumab ‚â•28 days <code>prior to elective surgery</code>.</li><li>Discontinue bevacizumab permanently if wound dehiscence and wound healing complications requiring medical intervention occur.</li></ul><img src=https://i.imgur.com/CY6qeGL.png alt="Example Image" class=RLQ><hr><a href=#hemorrhage><h3 id=hemorrhage><span class=hanchor arialabel=Anchor># </span>Hemorrhage</h3></a><ul><li>e.g., hemoptysis, GI bleeding, hematemesis, CNS hemorrhage, epistaxis, vaginal bleeding) reported.</li><li>Risk of severe or fatal pulmonary hemorrhage in patients with non-small cell lung cancer.</li><li>Serious or fatal pulmonary hemorrhage reported in 31% of patients with <strong>squamous cell</strong> histology and in 4% of patients with nonsquamous cell histology.</li><li>Mild hemorrhagic events, most commonly grade 1 <code>epistaxis</code>.</li></ul><hr><a href=#thromboembolism><h3 id=thromboembolism><span class=hanchor arialabel=Anchor># </span>Thromboembolism</h3></a><ul><li>e.g., cerebral infarction, TIA, MI, angina</li><li>Risk: history of arterial thromboembolism or patients >65 years of age.</li><li>Grade 3 or 4 venous thromboembolic events (e.g., DVT, intra-abdominal venous thrombosis) reported.</li><li>Increased risk of developing second thromboembolic event reported in patients with metastatic colorectal cancer receiving bevacizumab with chemotherapy despite use of full-dose warfarin therapy following an initial venous thromboembolic event.</li></ul><hr><a href=#hypertension><h3 id=hypertension><span class=hanchor arialabel=Anchor># </span>Hypertension</h3></a><ul><li>Monitor BP every 2‚Äì3 weeks during therapy.</li><li>If hypertension occurs, initiate appropriate antihypertensive therapy and monitor BP regularly.</li><li>Discontinue therapy permanently if hypertensive crisis or hypertensive encephalopathy occurs.</li><li>If therapy is discontinued because of hypertension, monitor BP at regular intervals thereafter.</li></ul><hr><a href=#reversible-posterior-leukoencephalopathy-syndrome-rpls><h3 id=reversible-posterior-leukoencephalopathy-syndrome-rpls><span class=hanchor arialabel=Anchor># </span>Reversible Posterior Leukoencephalopathy Syndrome (RPLS)</h3></a><ul><li>a.ka. brain-capillary leak syndrome</li><li>headache, seizure, lethargy, confusion, blindness, and other visual and neurologic disturbances;</li><li>occurred from 16 hours to 1 year after initiation of bevacizumab.</li><li><code>Magnetic resonance imaging (MRI)</code> is necessary to confirm diagnosis of RPLS.</li><li>Symptoms usually lessen or resolve within days of drug discontinuance, but some patients have experienced ongoing neurologic sequelae.</li><li>Risk of reinitiating bevacizumab in patients previously experiencing RPLS not known.</li></ul><hr><a href=#proteinuria><h3 id=proteinuria><span class=hanchor arialabel=Anchor># </span>Proteinuria</h3></a><ul><li>thrombotic microangiopathy on renal biopsy reported</li><li>serial urinalysis.</li><li>Further assessment (e.g., 24-hour urine collection) recommended if ‚â•2+ urine dipstick reading occurs.</li><li>Interrupt bevacizumab therapy for moderate proteinuria (‚â•2 g per 24 hours);</li><li>resume therapy when proteinuria is &lt;2 g per 24 hours.</li><li>Discontinue bevacizumab permanently in patients with nephrotic syndrome.</li></ul><hr><a href=#ocular-effects><h3 id=ocular-effects><span class=hanchor arialabel=Anchor># </span>Ocular Effects</h3></a><ul><li>Permanent loss of vision,</li><li>endophthalmitis (infectious and sterile),</li><li>intraocular inflammation, retinal detachment, increased IOP, hemorrhage (including conjunctival, vitreous, or retinal hemorrhage), vitreous floaters, ocular hyperemia, and ocular pain or discomfort</li></ul><img src=https://i.imgur.com/IJWAzP1.png alt="Example Image" class=RLQ><hr><a href=#as-first-line-therapy-bevacizumab-may-be-given-with><h2 id=as-first-line-therapy-bevacizumab-may-be-given-with><span class=hanchor arialabel=Anchor># </span>As first-line therapy, bevacizumab may be given with</h2></a><ul><li>FOLFOX, CAPEOX, or FOLFIRI</li><li>FOLFOXIRI in selected fit patients with cytoreduction as goal, and potentially in fit patients with mutated BRAF</li><li>fluoropyrimidines if aggressive treatments not tolerable</li></ul><hr><a href=#bevacizumab--irinotecan-fluorouracil-and-leucovorin-for-mcrc><h2 id=bevacizumab--irinotecan-fluorouracil-and-leucovorin-for-mcrc><span class=hanchor arialabel=Anchor># </span>Bevacizumab + irinotecan, fluorouracil, and leucovorin for mCRC</h2></a><a href=#nejm-2004><h4 id=nejm-2004><span class=hanchor arialabel=Anchor># </span>NEJM 2004</h4></a><p>:::columns</p><ul><li><code>Phase III</code> <code>Multi-center</code> <code>Double-blind</code></li><li>Number of patients: 813</li><li>Previously untreated metastatic colorectal cancer</li><li>Bevacizumab (5 mg/kg every two weeks)</li><li>Irinotecan, bolus fluorouracil, and leucovorin (IFL)</li><li>First-line</li></ul><p>:::split</p><table><thead><tr><th style=text-align:center>Endpoints</th><th style=text-align:center>IFL + Bevacizumab</th><th style=text-align:center>IFL + Placebo</th></tr></thead><tbody><tr><td style=text-align:center>PFS (months)</td><td style=text-align:center>10.6</td><td style=text-align:center>6.2</td></tr><tr><td style=text-align:center>RR (%)</td><td style=text-align:center>44.8</td><td style=text-align:center>34.8</td></tr><tr><td style=text-align:center>OS (months)</td><td style=text-align:center>20.3</td><td style=text-align:center>15.6</td></tr></tbody></table><p>:::</p><blockquote><p>Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., &mldr; & Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England journal of medicine, 350(23), 2335-2342.</p></blockquote><hr><a href=#bev-in-combination-with-xelox-or-folfox-4-improves-progression-free-survival-in-first-line-treatment-of-mcrc><h2 id=bev-in-combination-with-xelox-or-folfox-4-improves-progression-free-survival-in-first-line-treatment-of-mcrc><span class=hanchor arialabel=Anchor># </span>Bev in combination with XELOX or FOLFOX-4 Improves Progression-Free Survival in First-Line Treatment of MCRC</h2></a><ul><li>Phase: III</li><li>Number of patients: 1,401</li><li>Agent: Bev in combination with [XELOX] or [FOLFOX-4]</li><li>First-line</li></ul><table><thead><tr><th>Outcome</th><th>Bevacizumab</th><th>Placebo</th><th>Hazard Ratio (97.5% CI)</th><th>P Value</th></tr></thead><tbody><tr><td>Progression-Free Survival</td><td>9.4 months</td><td>8.0 months</td><td>0.83 (0.72-0.95)</td><td>0.0023</td></tr><tr><td>Overall Survival</td><td>21.3 months</td><td>19.9 months</td><td>0.89 (0.76-1.03)</td><td>0.077</td></tr></tbody></table><blockquote><p>Saltz, L. B., Clarke, S., D√≠az-Rubio, E., Scheithauer, W., Figer, A., Wong, R., &mldr; & Cassidy, J. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology, 26(12), 2013-2019.</p></blockquote><hr><a href=#in-the-tribe-study-for-bevfolfoxiri><h2 id=in-the-tribe-study-for-bevfolfoxiri><span class=hanchor arialabel=Anchor># </span>In the TRIBE study for Bev/FOLFOXIRI</h2></a><ol><li>Open-label, multicentre, <code>phase 3</code>, <code>508 patients</code> were enrolled.</li><li>First line for unresectable metastatic colorectal cancer.</li><li>Agent: FOLFOXIRI plus bevacizumab or FOLFIRI plus bevacizumab.</li><li>Trial Name or NCT Number: NCT00719797.</li></ol><table><thead><tr><th>Outcome</th><th>Experimental Group</th><th>Control Group</th><th>Hazard Ratio (95% CI)</th><th>P Value</th></tr></thead><tbody><tr><td>Progression-free Survival</td><td>12.1 months</td><td>9.7 months</td><td>0.75 (0.62 to 0.90)</td><td>0.003</td></tr><tr><td>Overall survival</td><td>31.0 months</td><td>25.8 months</td><td>0.79 (0.63 to 1.00)</td><td>0.054</td></tr><tr><td>Response rate</td><td>65%</td><td>53%</td><td>Not reported</td><td>0.006</td></tr></tbody></table><p>:::split</p><table><thead><tr><th>Molecular Subgroup</th><th>Median Overall Survival (months)</th><th>Hazard Ratio (95% CI)</th></tr></thead><tbody><tr><td>RAS and BRAF wt</td><td>37.1</td><td>Not reported</td></tr><tr><td>RAS-mutation</td><td>25.6</td><td>1.49 (1.11-1.99)</td></tr><tr><td>BRAF-mutation</td><td>13.4</td><td>2.79 (1.75-4.46)</td></tr></tbody></table><p>:::</p><hr><a href=#in-ras-wt-left-sided-mcrc><h4 id=in-ras-wt-left-sided-mcrc><span class=hanchor arialabel=Anchor># </span>In RAS wt, Left-sided mCRC</h4></a><a href=#comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-first-line-treatment-for-metastatic-colorectal-cancer><h2 id=comparison-of-chemotherapy-plus-bevacizumab-vs-cetuximab-in-first-line-treatment-for-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Comparison of Chemotherapy plus Bevacizumab vs Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer</h2></a><ul><li><strong>FIRE-3</strong>: 28.7 | 25.0</li><li><strong>CALGB-SWOG 80405</strong>: 29.93 | 29.04</li><li><strong>PARADIGM</strong>: 37.9 | 34.3</li></ul><hr><a href=#fire-3><h2 id=fire-3><span class=hanchor arialabel=Anchor># </span>FIRE-3</h2></a><ul><li>Open-label, randomized, <code>phase 3 trial</code></li><li>(1:1) to FOLFIRI + cetuximab or FOLFIRI + bevacizumab</li><li>592 patients with KRAS exon 2 wild-type tumors<ul><li>297 patients in the FOLFIRI plus cetuximab group</li><li>295 patients in the FOLFIRI plus bevacizumab group</li></ul></li><li>First-line treatment of metastatic colorectal cancer</li></ul><table><thead><tr><th>Outcome</th><th>Cetuximab Group</th><th>Bevacizumab Group</th><th>HR (95% CI)</th><th>P Value</th></tr></thead><tbody><tr><td>Objective Response Rate</td><td>62.0% (56.2-67.5)</td><td>58.0% (52.1-63.7)</td><td>1.18 (0.85-1.64)</td><td>0.18</td></tr><tr><td>Progression-Free Survival</td><td>10.0 months (8.8-10.8)</td><td>10.3 months (9.8-11.3)</td><td>1.06 (0.88-1.26)</td><td>0.55</td></tr><tr><td>Overall survival</td><td>28.7 months (24.0-36.6)</td><td>25.0 months (22.7-27.6)</td><td>0.77 (0.62-0.96)</td><td>0.017</td></tr></tbody></table><hr><a href=#summary><h2 id=summary><span class=hanchor arialabel=Anchor># </span>Summary</h2></a><ul><li>This randomized controlled trial compared the effectiveness of cetuximab and bevacizumab when added to FOLFIRI as first-line treatment for metastatic colorectal cancer in patients with KRAS exon 2 wild-type tumors.</li><li>patients treated with FOLFIRI plus cetuximab had longer overall survival compared to those treated with FOLFIRI plus bevacizumab.</li><li>FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.</li></ul><img src=https://i.imgur.com/ag1DyG6.png alt="Example Image" class=RLQ><hr><a href=#calgbswog-80405><h2 id=calgbswog-80405><span class=hanchor arialabel=Anchor># </span>CALGB/SWOG 80405</h2></a><ul><li>Multi-center Randomized 1137 patients</li><li>Patients with previously untreated advanced or metastatic colorectal cancer<ul><li>Tumors were KRAS wild-type (wt)</li></ul></li><li>Cetuximab or bevacizumab</li><li>Chemotherapy regimens: mFOLFOX6 or FOLFIRI</li><li>First-line treatment</li></ul><table><thead><tr><th>Outcome</th><th>Cetuximab + Chemotherapy Group</th><th>Bevacizumab + Chemotherapy Group</th><th>Hazard Ratio (95% CI)</th><th>P Value</th></tr></thead><tbody><tr><td>Overall Survival</td><td>29.93 months (27.56-31.21)</td><td>29.04 months (25.66-31.21)</td><td>0.92 (0.78-1.09)</td><td>0.34</td></tr><tr><td>Progression-Free Survival</td><td>10.45 months (9.66-11.33)</td><td>10.84 months (9.86-11.4)</td><td>Not reported</td><td>Not reported</td></tr></tbody></table><blockquote><p>SWOG, Southwest Oncology Group</p></blockquote><hr><a href=#calgbswog-80405-1><h4 id=calgbswog-80405-1><span class=hanchor arialabel=Anchor># </span>CALGB/SWOG 80405</h4></a><a href=#summary-1><h2 id=summary-1><span class=hanchor arialabel=Anchor># </span>Summary</h2></a><ul><li>ü§î cetuximab vs bevacizumab with mFOLFOX6 or FOLFIRI</li><li>no significant difference in overall survival, progression-free survival, or overall response rate between the cetuximab-chemotherapy group and the bevacizumab-chemotherapy group.</li></ul><img src=https://i.imgur.com/4t3QWxI.png alt="Example Image" class=RLQ><hr><a href=#paradigm><h2 id=paradigm><span class=hanchor arialabel=Anchor># </span>PARADIGM</h2></a><ul><li>Open-label</li><li>Multicenter</li><li>Randomized</li><li>Number of patients:</li><li>823 patients</li><li>Chemotherapy-naive RAS WT metastatic colorectal cancer (mCRC)</li><li>Left-sided primary tumors</li><li>Agents: Panitumumab plus mFOLFOX6 vs. Bevacizumab plus mFOLFOX6</li></ul><p><img src=https://i.imgur.com/wsY6DW0.png width=auto alt="bg right:50% height:550px"></p><hr><a href=#as-maintenance-therapy><h4 id=as-maintenance-therapy><span class=hanchor arialabel=Anchor># </span>As maintenance therapy</h4></a><a href=#continued-use-of-bevacizumab-in--progressing-after-standard-first-line-bevacizumab-based-treatment><h2 id=continued-use-of-bevacizumab-in--progressing-after-standard-first-line-bevacizumab-based-treatment><span class=hanchor arialabel=Anchor># </span>Continued use of bevacizumab in progressing after standard first-line bevacizumab-based treatment</h2></a><ul><li>Open-label, <code>phase 3 study</code> RCT</li><li>820 patients in total (1:1)</li><li>Patients progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy</li><li>Bevacizumab plus standard second-line chemotherapy</li><li>Choice between oxaliplatin-based or irinotecan-based second-line chemotherapy depended on the first-line regimen (switch of chemotherapy)</li></ul><blockquote><p>Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology. 2013;14(1):29-37. doi:10.1016/S1470-2045(12)70477-1</p></blockquote><hr><a href=#result><h3 id=result><span class=hanchor arialabel=Anchor># </span>Result</h3></a><table><thead><tr><th>Outcome</th><th>Bevacizumab plus chemotherapy</th><th>Chemotherapy alone</th></tr></thead><tbody><tr><td>Median overall survival (months)</td><td>11.2 (95% CI 10.4-12.2)</td><td>9.8 (95% CI 8.9-10.7)</td></tr><tr><td>Hazard ratio</td><td>0.81</td><td></td></tr><tr><td>Unstratified log-rank test p-value</td><td>0.0062</td><td></td></tr><tr><td>Grade 3-5 bleeding or hemorrhage</td><td>8 (2%)</td><td>1 (&lt;1%)</td></tr><tr><td>Gastrointestinal perforation</td><td>7 (2%)</td><td>3 (&lt;1%)</td></tr><tr><td>Venous thromboembolisms</td><td>19 (5%)</td><td>12 (3%)</td></tr></tbody></table><hr><a href=#second-line-treatment><h1 id=second-line-treatment><span class=hanchor arialabel=Anchor># </span>Second Line Treatment</h1></a><hr><a href=#bevacizumab-vs-cetuximab-in-second-line-treatment><h2 id=bevacizumab-vs-cetuximab-in-second-line-treatment><span class=hanchor arialabel=Anchor># </span>Bevacizumab vs Cetuximab in Second-Line Treatment</h2></a><ul><li>A Phase 2 trial Open-label Multicenter Randomized, 132 patients</li><li>Disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer</li><li>Arm A: FOLFIRI or modified FOLFOX6 plus bevacizumab</li><li>Arm B: FOLFIRI or modified FOLFOX6 plus cetuximab</li><li>Second-line treatment</li><li><code>PRODIGE18</code> (Partenariat de Recherche en Oncologie DIGEstive) study</li></ul><hr><a href=#comparison-of-two-groups><h3 id=comparison-of-two-groups><span class=hanchor arialabel=Anchor># </span>Comparison of Two Groups</h3></a><table><thead><tr><th>Endpoint</th><th>Arm A</th><th>Arm B</th></tr></thead><tbody><tr><td>4-month PFS rate</td><td>80.3% (95% CI, 68.0%-88.3%)</td><td>66.7% (95% CI, 53.6%-76.8%)</td></tr><tr><td>Median PFS</td><td>7.1 months (95% CI, 5.7-8.2 months)</td><td>5.6 months (95% CI, 4.2-6.5 months)</td></tr><tr><td>Hazard ratio (PFS)</td><td>0.71 (95% CI, 0.50-1.02)</td><td>Not reported</td></tr><tr><td>Median OS</td><td>15.8 months (95% CI, 9.5-22.3 months)</td><td>10.4 months (95% CI, 7.0-16.2 months)</td></tr><tr><td>Hazard ratio (OS)</td><td>0.69 (95% CI, 0.46-1.04)</td><td>Not reported</td></tr></tbody></table><ul><li>nonsignificant difference but favored continuation of bevacizumab</li></ul><hr><a href=#aflibercept-in-combination-with-folfiri-for-metastatic-colorectal-cancer-a-randomized-phase-iii-trial><h2 id=aflibercept-in-combination-with-folfiri-for-metastatic-colorectal-cancer-a-randomized-phase-iii-trial><span class=hanchor arialabel=Anchor># </span>Aflibercept in Combination with FOLFIRI for Metastatic Colorectal Cancer: A Randomized Phase III Trial</h2></a><ul><li>randomized, double-blind, placebo-controlled phase III trial</li><li>1226 patients (612 received aflibercept and 614 received placebo)</li><li>metastatic colorectal cancer previously treated with oxaliplatin, including patients who received prior bevacizumab</li><li>Agent: Aflibercept (also known as ziv-aflibercept in the United States) in combination with <strong>FOLFIRI</strong></li><li>second-line or later</li><li>NCT Number: NCT00561470</li></ul><hr><table><thead><tr><th>Group</th><th>Progression-free survival (PFS)</th><th>Overall survival (OS)</th><th>Response rate (RR)</th></tr></thead><tbody><tr><td>Aflibercept + FOLFIRI</td><td>Median PFS of 6.90 months</td><td>Median OS of 13.50 months</td><td>19.8%</td></tr><tr><td>Placebo + FOLFIRI</td><td>Median PFS of 4.67 months</td><td>Median OS of 12.06 months</td><td>11.1%</td></tr></tbody></table><a href=#summary-2><h2 id=summary-2><span class=hanchor arialabel=Anchor># </span>Summary</h2></a><ul><li>The addition of aflibercept to FOLFIRI significantly improved overall survival and progression-free survival in patients with metastatic colorectal cancer previously treated with oxaliplatin, including those who received prior bevacizumab. However, the combination also resulted in increased toxicity.</li></ul><hr><a href=#drug-info-‚Ñπ-1><h4 id=drug-info-‚Ñπ-1><span class=hanchor arialabel=Anchor># </span>Drug Info ‚ÑπÔ∏è</h4></a><a href=#ziv-aflibercept-zaltrap><h2 id=ziv-aflibercept-zaltrap><span class=hanchor arialabel=Anchor># </span>Ziv-Aflibercept (Zaltrap)</h2></a><ul><li>Dosing: <code>4 mg/kg</code> IV every 2 wks. No renal or hepatic dose adjustments recommended</li><li>PK/PD: T1/2 ‚àº6 d</li><li>AEs:<ul><li>GI perforation (BBW), hemorrhage (BBW), impaired wound healing (BBW), proteinuria, HTN, thromboembolism, ‚Üë LFTs</li></ul></li><li>DDI:</li><li>Contraindicated w/ clozapine (‚Üë risk of agranulocytosis)</li><li>Clinical pearls:<ul><li>Monitor CBC, urine protein, BP, & signs of bleeding. Hold Rx at least 4 wks prior & 4 wks after major elective surgery</li></ul></li></ul><hr><a href=#comparing-second-line-bevacizumab-and-aflibercept-in-patients-who-progressed-on-first-line-bevacizumab><h2 id=comparing-second-line-bevacizumab-and-aflibercept-in-patients-who-progressed-on-first-line-bevacizumab><span class=hanchor arialabel=Anchor># </span>Comparing second-line bevacizumab and aflibercept in patients who progressed on first-line bevacizumab</h2></a><p>:::columns</p><ul><li>a multicenter retrospective analysis</li><li>681 patients were included, 326 aflibercept and 355 beva<ul><li>Agent: Bevacizumab or Aflibercept added to FOLFIRI in second-line treatment.</li></ul></li><li>Second-line treatment for mCRC after failure of first-line FOLFOX-bevacizumab.</li></ul><p>:::split</p><table><thead><tr><th>Group/Outcome</th><th>FOLFIRI-bevacizumab</th><th>FOLFIRI-aflibercept</th></tr></thead><tbody><tr><td>Median OS</td><td>13.0 months</td><td>10.4 months</td></tr><tr><td>Hazard Ratio for Death</td><td>0.71</td><td>Not reported</td></tr></tbody></table><p>:::</p><blockquote><p>Torregrosa C, Pernot S, Vaflard P, et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. International Journal of Cancer. 2022;151(11):1978-1988. doi:10.1002/ijc.34166</p></blockquote><hr><a href=#raise-trial><h2 id=raise-trial><span class=hanchor arialabel=Anchor># </span>RAISE Trial</h2></a><ul><li>Multicentre, randomised, double-blind, phase 3 RAISE trial</li><li>Randomised (1:1) via a centralised, interactive voice-response system to receive 8 mg/kg intravenous ramucirumab plus FOLFIRI or matching placebo plus FOLFIRI every 2 weeks until disease progression</li><li>1072 patients (536 in each group)</li><li>disease progression during or within 6 months of the last dose of first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.</li><li>Second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan)</li><li>Trial Name: RAISE trial (NCT01183780)</li></ul><blockquote><p>Tabernero, Josep, et al. &ldquo;Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.&rdquo; The Lancet Oncology 16.5 (2015): 499-508.</p></blockquote><hr><table><thead><tr><th>Outcome Measures</th><th>Ramucirumab + FOLFIRI</th><th>Placebo + FOLFIRI</th></tr></thead><tbody><tr><td>Median overall survival (months)</td><td>13.3 (95% CI 12.4-14.5)</td><td>11.7 (10.8-12.7)</td></tr><tr><td>Hazard ratio</td><td>0.844 95% CI 0.730-0.976</td><td>-</td></tr></tbody></table><table><thead><tr><th>Outcome Measures</th><th>Ramucirumab + FOLFIRI</th><th>Placebo + FOLFIRI</th></tr></thead><tbody><tr><td>Neutropenia (‚â•Grade 3)</td><td>203 (38%)</td><td>123 (23%)</td></tr><tr><td>Hypertension (‚â•Grade 3)</td><td>59 (11%)</td><td>15 (3%)</td></tr><tr><td>Diarrhoea (‚â•Grade 3)</td><td>57 (11%)</td><td>51 (10%)</td></tr><tr><td>Febrile neutropenia incidence</td><td>18 (3%)</td><td>13 (2%)</td></tr><tr><td>Fatigue (‚â•Grade 3)</td><td>61 (12%)</td><td>41 (8%)</td></tr></tbody></table><a href=#summary-3><h2 id=summary-3><span class=hanchor arialabel=Anchor># </span>Summary</h2></a><p>Ramucirumab plus FOLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma. No unexpected adverse events were identified and toxic effects were manageable.</p><hr><a href=#drug-info-‚Ñπ-2><h4 id=drug-info-‚Ñπ-2><span class=hanchor arialabel=Anchor># </span>Drug Info ‚ÑπÔ∏è</h4></a><a href=#ramucirumab-cyramza><h2 id=ramucirumab-cyramza><span class=hanchor arialabel=Anchor># </span>Ramucirumab (Cyramza)</h2></a><ul><li>Dosing:<ul><li>Dosing dependent on dz;<ul><li>colorectal/gastric: 8 mg/kg IV every 2 wks as part of combination therapy;</li><li>NSCLC 10 mg/kg every 21 d w/ docetaxel</li></ul></li></ul></li><li>PK/PD: T1/2 ‚àº14 d</li><li>AEs: HTN, diarrhea, proteinuria, neutropenia, anemia, infusion-related rxns</li><li>DDI: No known pathways of metabolism</li><li>Clinical pearls:<ul><li>Premedications required; pts w/ HTN should be controlled prior to administration & BPs monitored closely</li></ul></li></ul><hr><a href=#wrap-up><h2 id=wrap-up><span class=hanchor arialabel=Anchor># </span>Wrap up</h2></a><ul><li>fast progressors: in bevacizumab-based first-line therapy, consider either ziv-aflibercept or ramucirumab plus FOLFIRI</li><li>progress on non-irinotecan-containing therapy, either ziv-aflibercept or ramucirumab plus either FOLFORI or irinotecan may be considered</li><li>bevacizumab preferred over ziv-aflibercept and ramucirumab</li></ul><img src=https://i.imgur.com/wO1xIje.png alt="Example Image" class=RLQ><hr><a href=#anti-vegf-as-third-line-therapy><h1 id=anti-vegf-as-third-line-therapy><span class=hanchor arialabel=Anchor># </span>Anti-VEGF as third-line therapy</h1></a><ul><li>Bevacizumab</li><li>Regorafenib</li></ul><img src=https://i.imgur.com/HfaJio9.png alt="Example Image" class=RLQ><hr><a href=#correct-regorafenib-alone><h2 id=correct-regorafenib-alone><span class=hanchor arialabel=Anchor># </span>CORRECT: regorafenib alone</h2></a><ol><li>phase 3 trial.</li><li>760pts : regorafenib (n=505) or placebo (n=255), and 753 patients initiated treatment.</li><li>progression during or within 3 months after the last standard therapy. Treatment line: Treatment-refractory metastatic colorectal cancer after all standard therapies.</li></ol><table><thead><tr><th>Group/Outcome</th><th>Regorafenib</th><th>Placebo</th></tr></thead><tbody><tr><td>Median Overall Survival</td><td>6.4 months</td><td>5.0 months</td></tr><tr><td>Hazard Ratio for Death</td><td>0.77</td><td>Not reported</td></tr><tr><td>Treatment-related adverse events</td><td>93%</td><td>61%</td></tr></tbody></table><hr><a href=#correct-regorafenib-alone-1><h4 id=correct-regorafenib-alone-1><span class=hanchor arialabel=Anchor># </span>CORRECT: regorafenib alone</h4></a><a href=#summary-4><h2 id=summary-4><span class=hanchor arialabel=Anchor># </span>Summary</h2></a><ul><li>The group receiving regorafenib had more grade 3 or 4 hand-foot skin reaction (17 versus 0.4 percent), fatigue (10 versus 5 percent), hypertension (7 versus 1 percent), diarrhea (7 versus 1 percent), and skin rash (6 versus 0 percent).</li><li>Fatal hepatic failure occurred in 1.6 percent of patients treated with regorafenib versus 0.4 percent in the placebo group.</li></ul><hr><a href=#concur-trial-with-chemo><h2 id=concur-trial-with-chemo><span class=hanchor arialabel=Anchor># </span>CONCUR trial: with chemo</h2></a><ul><li>Randomized, double-blind, placebo-controlled, phase III trial.</li><li>204 patients were randomized to receive either regorafenib (n = 136) or placebo (n = 68).</li><li>progressed within 3 months after completing standard therapy.</li><li>must have received at least 2 prior treatment lines for mCRC, which included a fluoropyrimidine, oxaliplatin, and irinotecan.</li><li>Prior anti-VEGF or anti-EGFR targeted therapy was allowed, but not required.</li></ul><table><thead><tr><th>Group/Outcome</th><th>Regorafenib</th><th>Placebo</th></tr></thead><tbody><tr><td>Median Overall Survival</td><td>8.8 months</td><td>6.3 months</td></tr><tr><td>Hazard Ratio for Death</td><td>0.550</td><td>-</td></tr><tr><td>Median PFS</td><td>3.2 months</td><td>1.7 months</td></tr><tr><td>Disease Control Rate (DCR)</td><td>52%</td><td>7%</td></tr></tbody></table><hr><a href=#redos-trial-reduce-dose><h2 id=redos-trial-reduce-dose><span class=hanchor arialabel=Anchor># </span>ReDOS trial: Reduce dose</h2></a><ul><li>ü´† 160 mg daily for 21 days of every 28-day cycle) may be too high</li><li>starting with 80 mg daily, escalating weekly in the absence of treatment-related toxicity to a target of 160 mg daily</li><li>OS 9.8 versus 6 months, and toxicity was more favorable.</li></ul><p><img src=https://i.imgur.com/xYLNMKJ.png width=auto alt="Figure: height:150px"></p><p><img src=https://i.imgur.com/c1mcpJp.png width=auto alt="bg right:50% height:650px"></p><hr><a href=#drug-info-‚Ñπ-3><h4 id=drug-info-‚Ñπ-3><span class=hanchor arialabel=Anchor># </span>Drug Info ‚ÑπÔ∏è</h4></a><a href=#regorafenib-stivarga><h2 id=regorafenib-stivarga><span class=hanchor arialabel=Anchor># </span>Regorafenib (Stivarga)</h2></a><ul><li>Dosing: 160 mg PO daily √ó 21 d of a 28-d cycle.<ul><li>No renal or hepatic dose adjustments recommended. Adjust dose for Rx-induced tox</li></ul></li><li>AEs:<ul><li>HTN, palmar plantar erythrodysesthesia, diarrhea, mucositis, fatigue, electrolyte imbalances, hematologic, hepatic, GI, proteinuria, cardiac, wound healing impairment</li></ul></li><li>DDI:<ul><li>CYP3A4 inhibitors/inducers (‚Üë/‚Üì conc. of regorafenib), warfarin (‚Üë/‚Üì warfarin effects)</li></ul></li><li>Clinical pearls:<ul><li>Take w/ low-fat breakfast. Discontinue at least 2 wks prior to surgery (wound healing). Monitor: Blood pressure, rash, LFTs, electrolytes, CBC</li></ul></li></ul><hr><a href=#regorafenib-versus-trifluridinetipiracil><h2 id=regorafenib-versus-trifluridinetipiracil><span class=hanchor arialabel=Anchor># </span>Regorafenib Versus Trifluridine/Tipiracil</h2></a><ul><li>Retrospective <code>observational study</code></li><li>223 patients in the regorafenib group and 327 patients in the trifluridine/tipiracil</li><li>Regorafenib and trifluridine/tipiracil in refractory to standard chemotherapy</li></ul><table><thead><tr><th>Group</th><th>Overall survival (OS)</th></tr></thead><tbody><tr><td>Regorafenib</td><td>Median OS of 7.9 months</td></tr><tr><td>Trifluridine/tipiracil</td><td>Median OS of 7.4 months</td></tr></tbody></table><ul><li>No significant difference in OS between regorafenib and trifluridine/tipiracil was observed in patients with mCRC.</li><li>In the subgroup analysis, regorafenib showed favorable survival in patients <code>aged &lt;65 years</code>,</li><li>whereas trifluridine/tipiracil was favored in patients <code>aged ‚â•65 years</code></li></ul><hr><a href=#ftd-tpi-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-phase-3-trial><h2 id=ftd-tpi-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-phase-3-trial><span class=hanchor arialabel=Anchor># </span>FTD-TPI Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Phase 3 Trial</h2></a><a href=#nejm-2023><h4 id=nejm-2023><span class=hanchor arialabel=Anchor># </span>NEJM 2023</h4></a><ul><li>492 patients<ul><li>Adult patients with refractory metastatic colorectal cancer</li><li>Received no more than two previous chemotherapy regimens</li></ul></li><li>Trifluridine-tipiracil (FTD-TPI) with or without Bevacizumab</li><li>Third-line or later chemotherapy</li><li>SUNLIGHT NCT04737187</li></ul><hr><table><thead><tr><th>Endpoint</th><th>Combination Group (n=246)</th><th>FTD-TPI Group (n=246)</th><th>Hazard Ratio (95% CI)</th><th>P-value</th></tr></thead><tbody><tr><td>Overall Survival (months)</td><td>10.8</td><td>7.5</td><td>0.61 (0.49 to 0.77)</td><td>&lt;0.001</td></tr><tr><td>Progression-Free Survival (months)</td><td>5.6</td><td>2.4</td><td>0.44 (0.36 to 0.54)</td><td>&lt;0.001</td></tr><tr><td>Response Rate</td><td>48.5%</td><td>24.6%</td><td>-</td><td>&lt;0.001</td></tr></tbody></table><ul><li>common adverse events in both groups were neutropenia, nausea, and anemia</li></ul><a href=#summary-5><h3 id=summary-5><span class=hanchor arialabel=Anchor># </span>Summary</h3></a><ul><li>FTD-TPI plus bevacizumab significantly prolonged OS and PFS</li><li>The combination therapy was well-tolerated with manageable adverse events.</li><li>addition of bevacizumab to FTD-TPI may be an effective treatment option for patients with advanced colorectal cancer who have received prior chemotherapy regimens.</li></ul><hr><p><img src=https://i.imgur.com/Z1ND8JN.png width=auto alt="bg height:750px"></p><hr><a href=#anti-vegf-in-older-adult-patients><h1 id=anti-vegf-in-older-adult-patients><span class=hanchor arialabel=Anchor># </span>Anti-VEGF in older adult patients</h1></a><a href=#and-those-with-a-poor-performance-status><h3 id=and-those-with-a-poor-performance-status><span class=hanchor arialabel=Anchor># </span>and those with a poor performance status</h3></a><img src=https://i.imgur.com/wmMvAkn.png alt="Example Image" class=RLQ><hr><a href=#phase-ii-prodige-20><h2 id=phase-ii-prodige-20><span class=hanchor arialabel=Anchor># </span>Phase II PRODIGE 20</h2></a><ul><li>Design: Randomized trial. 102 pts.</li><li>Patients aged 75 years and over with metastatic colorectal cancer.</li><li>Treatment line: Front line chemotherapy.</li></ul><table><thead><tr><th>Group/Outcome</th><th>Bevacizumab + CT</th><th>CT</th></tr></thead><tbody><tr><td>Efficacy (met primary endpoint)</td><td>50%</td><td>58%</td></tr><tr><td>Safety (met primary endpoint)</td><td>61%</td><td>71%</td></tr><tr><td>Median PFS</td><td>9.7 months</td><td>7.8 months</td></tr><tr><td>Median OS</td><td>21.7 months</td><td>19.8 months</td></tr><tr><td>36-month OS rate</td><td>27%</td><td>10.1%</td></tr></tbody></table><ul><li>significantly higher rate of grade 3 or 4 arterial hypertension (14 versus 6 percent)</li></ul><hr><a href=#bevacizumab-plus-capecitabine-in-elderly-patients-with-metastatic-colorectal-cancer-a-randomized-phase-3-trial><h2 id=bevacizumab-plus-capecitabine-in-elderly-patients-with-metastatic-colorectal-cancer-a-randomized-phase-3-trial><span class=hanchor arialabel=Anchor># </span>Bevacizumab plus Capecitabine in Elderly Patients with Metastatic Colorectal Cancer: A Randomized, Phase 3 Trial</h2></a><a href=#avex-trial><h3 id=avex-trial><span class=hanchor arialabel=Anchor># </span>AVEX trial</h3></a><ul><li><code>phase III</code>, Number of patients: 280</li><li>Age: median age of 76 (range 70-87)</li><li>As First-line treatment, for previously untreated, unresectable, metastatic colorectal cancer</li><li>Not candidates for oxaliplatin-based or irinotecan-based chemotherapy regimens</li><li>Capecitabine</li><li>Bevacizumab (7¬∑5 mg/kg intravenously on day 1)</li></ul><blockquote><p>Cunningham, David, et al. &ldquo;Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.&rdquo; The lancet oncology 14.11 (2013): 1077-1085.</p></blockquote><hr><a href=#bevacizumab-plus-capecitabine><h4 id=bevacizumab-plus-capecitabine><span class=hanchor arialabel=Anchor># </span>Bevacizumab plus capecitabine</h4></a><table><thead><tr><th>Outcome</th><th>Bevacizumab plus capecitabine</th><th>Capecitabine alone</th></tr></thead><tbody><tr><td>Progression-free survival (months)</td><td>9.1 [95% CI 7.3-11.4]</td><td>5.1 [4.2-6.3]</td></tr><tr><td>Hazard ratio</td><td>0.53 [0.41-0.69]</td><td>-</td></tr><tr><td>p-value</td><td>&lt;0.0001</td><td>-</td></tr><tr><td>Overall survival (months)</td><td>not reported</td><td>not reported</td></tr><tr><td>Response rate</td><td>not reported</td><td>not reported</td></tr></tbody></table><a href=#summary-6><h3 id=summary-6><span class=hanchor arialabel=Anchor># </span>Summary</h3></a><ul><li>The addition of bevacizumab to capecitabine significantly improved progression-free survival compared with capecitabine alone, although treatment-related adverse events were more frequent in the combination group.</li></ul><hr><a href=#should-i-add-anti-vegf-in-older-adult-patients-and-those-with-a-poor-performance-status><h3 id=should-i-add-anti-vegf-in-older-adult-patients-and-those-with-a-poor-performance-status><span class=hanchor arialabel=Anchor># </span>Should I add Anti-VEGF in older adult patients and those with a poor performance status?</h3></a><ul><li>For the older age group, the median OS benefit from adding bevacizumab was only <code>3.3</code> months (median 17.4 versus 14.1 months, HR 0.79, 95% CI 0.66-0.93).</li><li>Bleeding, hypertension, proteinuria, ATEs, venous thromboembolic events, wound-healing complications, fistulae, gastrointestinal perforation, and congestive heart failure were all more common in bevacizumab-treated patients.</li><li>Among individuals 70 and older, the risk an arterial thrombotic event was twofold higher in the bevacizumab group (6.7 versus 3.2 percent).</li></ul><hr><a href=#take-home-messages><h2 id=take-home-messages><span class=hanchor arialabel=Anchor># </span>Take Home Messages</h2></a><p>anti-VEGF AEs: Ë°ÄÊ†ìÂá∫Ë°ÄËõãÁôΩÂ∞ø„ÄÅË°ìÂæåÂÇ∑Âè£È´òË°ÄÂ£ì</p><hr><p>:::columns</p><ul><li>1L: cet vs bev<ul><li><strong>FIRE-3</strong>: 28.7 | 25.0</li><li><strong>CALGB-SWOG 80405</strong>: 29.93 | 29.04</li><li><strong>PARADIGM</strong>: 37.9 | 34.3</li></ul></li></ul><p>:::split</p><ul><li>2L: all regimens ¬±<ul><li>Bev: <strong>ML18147</strong> : 11.2 | 9.8:</li><li>ziv-aflib 4mg/kg: <strong>VELOUR</strong>: 13.5 | 12.6</li><li>Ramu: <strong>RAISE</strong>: 13.6 | 11.7:</li></ul></li><li>Bev > ziv-aflibercept/ramucirumab<ul><li>because of tox, cost</li></ul></li></ul><p>:::</p><ul><li>3rd line:<ul><li>monoRx regorafenib: <strong>CORRECT</strong>: 6.4 | 5.0 ; w/ chemo: <strong>CONCUR</strong> : 8.8 | 6.3</li><li>TAS-102 + Beva: <strong>SUNLIGHT</strong> : 10.8 | 7.5</li></ul></li></ul><hr><a href=#thank-you-for-your-time-and-attention><h1 id=thank-you-for-your-time-and-attention><span class=hanchor arialabel=Anchor># </span>Thank you for your time and attention</h1></a><a href=#_have-a-nice-day_><h1 id=_have-a-nice-day_><span class=hanchor arialabel=Anchor># </span><em>Have a nice day</em></h1></a><img src=https://i.imgur.com/vnMETFG.png alt="Example Image" class=RLQ></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>‚Ü©Ô∏è ÂèçÂêëÈÄ£Áµê</h3><ul class=backlinks><li>ü§≠Ê≤íÊúâÊâæÂà∞ÂèçÂêëÈÄ£Áµê</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ü§Ø‰∫íÂãïÂúñ</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>Êú¨Á∂≤Á´ôÊòØÁî± Hsieh-Ting Lin ‰ª•‚ù§Ô∏è Áî® <a href=https://github.com/jackyzha0/quartz>Quartz</a>ÈÄôÂÄãÈÖ∑Êù±Ë•øÁ®ÆÂá∫‰æÜü™¥ , ¬© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>üè†È¶ñÈ†Å</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>